<PAGE>
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
_________________________
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
_________________________
DATE OF REPORT: JULY 14, 1998
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
===============================================================================
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. announced that it has received a notice of
allowance regarding 79 claims on its patent application covering its light-
and laser-based imaging technology, as more fully described in the Company's
Press Release dated July 14, 1998, filed as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated July 14, 1998, announcing U.S. patent
and Trademark Office notice of allowance regarding imaging patent
application.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
--------------------------
Date: July 14, 1998 John Smolik, President
-1-
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
No. Description
- --- -----------
<S> <C>
99 Press release of the Company, dated July 14, 1998, announcing U.S.
Patent and Trademark Office notice of allowance recording imaging
patent application.
</TABLE>
-2-
<PAGE>
[PHOTOGEN LETTERHEAD]
FOR IMMEDIATE RELEASE CONTACT: ROBERT CATHEY
ACKERMANN PUBLIC RELATIONS & MARKETING
(423) 584-0550 or [email protected]
PATENT OFFICE ALLOWANCE PROTECTS DEVELOPMENT OF
ADVANCED SOFT-TISSUE IMAGING TECHNOLOGY
KNOXVILLE, TENN. - JULY 14, 1998 - Photogen Technologies, Inc. (OTC-PHGN) has
received from the U.S. Patent and Trademark Office a Notice of Allowance
approving 79 claims on the Company's patent application covering its light-
and laser-based imaging technology.
Company scientists are working toward the development of proprietary light-
and laser-based technologies to enhance the safety and efficacy of
photodynamic therapy and photodynamic imaging for the diagnosis and treatment
of cancer, infectious diseases and other medical conditions. Technology
developed from the imaging patent would employ light-activated imaging agents
to detect diagnostically significant features at a cellular level.
As a result of this Notice of Allowance, the Company expects the Patent and
Trademark Office to issue a patent covering those claims.
Through its imaging technology, Photogen Technologies hopes to identify and
diagnose disease by applying light energy delivered via its two-photon
excitation technology to photoactive agents that contain a targeting molecule
making them preferentially absorbed in diseased cells. This imaging
technology has not been demonstrated in animal or human clinical trials.
"This technology offers the potential for a new generation of soft tissue
imaging," said John Smolik, president of Photogen. "Our early lab work
indicates that a photodynamic-based approach - which our new patent will
protect our ability to exploit - might well resolve smaller biological
features and detect disease earlier than possible with current X-ray
technology. Also, a photodynamic approach to soft-tissue imaging eliminates
potential health issues associated with repeated exposure to X-rays."
The Company previously received a Patent and Trademark Office Notice of
Allowance for over 60 claims relating to the use of two-photon excitation for
therapeutic purposes. These proprietary
(more)
<PAGE>
PHOTOGEN TECHNOLOGIES RECEIVES NOTICE OF ALLOWANCE / 2
technologies use two-photon excitation to deliver light to particular sites
in tissue and activate photodynamic drugs for the purpose of treating a
variety of diseases.
Photogen Technologies, Inc., through its wholly owned subsidiary - Photogen,
Inc. - is a development-stage Company focused on creating
photodynamic-related health care products based on its proprietary two-photon
excitation and related technology. The Company has discovered new methods for
using laser-generated light to activate photoactive agents within deep tissue
sufficient to produce a range of beneficial therapeutic and diagnostic
outcomes. These technologies involve methods, materials and devices that may
be used to produce light and photoactive agents that will destroy diseased
cells, remove tissue or identify and diagnose disease.
This news release may contain forward-looking statements that involve risks
and uncertainties. The Company has no products or operating revenues at this
time. A full discussion of the Company's operations and financial condition,
including risk factors that may affect the Company's business and future
prospects, is contained in documents the Company files with the Securities
and Exchange Commission, such as the Company's Form 10-SB and the Company's
reports on Form 10-QSB and Form 10-KSB. These documents identify important
factors that could cause the Company's actual performance to differ from
current expectations. The common stock of Photogen Technologies, Inc. is
traded on the over-the-counter bulletin board market under the symbol PHGN.
For information, contact Robert Cathey at Ackermann Public Relations &
Marketing, 423/584-0550, e-mail: [email protected]. Or, visit our World
Wide Web site, at www.photogen.com.
# # #
Photogen is a trademark of Photogen Technologies, Inc.
